Drug Profile
CC 8464
Alternative Names: ASP-1807; CC-8464Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Chromocell Corporation
- Class Analgesics; Antirheumatics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Erythromelalgia; Neuropathic pain
- Discontinued Diabetic neuropathies; Osteoarthritis; Sciatica
Most Recent Events
- 09 Apr 2024 Adverse events data from a phase I trial in Neuropathic pain released by Chromocell
- 09 Apr 2024 Chromocell completes a phase I clinical trials in Neuropathic pain in USA (PO)
- 09 Apr 2024 Chromocell plans a phase II trial for either Erythromelalgia or Idiopathic small fiber neuropathy (PO)